Loading
Skopos Bio is a Melbourne spin-out from the Peter MacCallum Cancer Centre developing radioactive drugs that home in on cancer cells, including targets ordinary drugs struggle to reach. It launched in October 2026 with seed funding to reach first human trials.
Skopos Bio is a spin-out from the Peter MacCallum Cancer Centre in Melbourne, based at the Jumar Bioincubator, developing next-generation radiopharmaceutical therapies. Its founders are Professor Michael Hofman, Associate Professor Mohammad Haskali and Associate Professor Luc Furic. It announced its launch in early October 2026 with an AUD 12 million seed round led by Tenmile, Tin Alley Ventures and Yosemite, intended to take its first programme into human trials. Targets and isotopes have not been disclosed.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Seed · AUD 12 million per SmartCompany (2 October 2026); some databases report about USD 8.3 million. No USD figure from the company. | 2026 | undisclosed | smartcompany.com.au |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/